Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104452 | 0.88 | PKM (0.59) | TDP1HPGDKDM4EPOLBCTDSP1 | |
| SCHEMBL16955551 | 0.88 | TDP1 (0.50) | TDP1HPGDKDM4EPOLBCTDSP1 | |
| SCHEMBL29740471 | 0.88 | PKM (0.59) | TDP1HPGDKDM4EPOLBCTDSP1 | |
| SCHEMBL28390304 | 0.87 | MAPT (0.60) | TDP1HPGDKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL1977244 | 0.85 | HPGD (0.49) | TDP1HPGDKDM4EPOLBCTDSP1 | |
| SCHEMBL167965 | 0.85 | TDP1 (0.61) | TDP1HPGDKDM4EPOLBCTDSP1 | |
| SCHEMBL2521491 | 0.85 | HPGD (0.52) | TDP1HPGDKDM4EPOLBCTDSP1 | |
| SCHEMBL30542564 | 0.85 | TDP1 (0.61) | TDP1HPGDKDM4EPOLBCTDSP1 | |
| SCHEMBL10908860 | 0.84 | POLB (0.47) | KDM4EPOLBL3MBTL1SMN1; SMN2RAB9A | |
| SCHEMBL9747334 | 0.83 | MAPT (0.48) | TDP1HPGDKDM4EPOLBCTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251617-B1 | (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024003535-A2 | COMPOUNDS | UNIVERSITY OF DUNDEE (GB) | 2024-01-04 | — | — | WO | disclosed |
| US-20230416233-A1 | (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-12-28 | — | — | US | disclosed |
| CN-116583510-A | (aza) quinolin-4-amine derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-3307067-B1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-111646973-B | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-19 | — | — | CN | disclosed |
| CN-111646973-A | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-09-11 | — | — | CN | disclosed |
| US-10688082-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| EP-2984088-B1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES LLC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20180193314-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2018-07-12 | — | — | US | disclosed |
| WO-2013050527-A1 | QUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-04-11 | — | — | WO | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7364881-B1 | Biological process for the conversion of nitroarenes to ortho-aminophenols using recombinant E. coli strains | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2008-04-29 | — | — | US | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-4666499-A | Herbicidal 2 methyl-4-phosphinylcinnolinium hydroxide inner salts | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-05-19 | — | — | US | disclosed |
| US-4620000-A | Method for preparing 4-hydroxycinnolines in a pH controlled system | SHELL OIL COMPANY (US) | 1986-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688082-B2 | Aminopyrazine compounds with A2A antagonist properties | ADORA2A, ADORA1, ADORA3 | TDP1 1310/4885HPGD 2922/4885KDM4E 2946/4885 |
| US-20180193314-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA1, ADORA3 | TDP1 1310/4885HPGD 2922/4885KDM4E 2946/4885 |
| US-20230416233-A1 | (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | TDP1 2458/4885HPGD 802/4885KDM4E 1552/4885 |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | TDP1 1158/4885HPGD 969/4885KDM4E 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.